1-3 of 3
Kathleen Turnbull, MD
Close
Sort by
Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update

Tim H. Brümmendorf, MD, Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Carlo Gambacorti-Passerini, MD, Jeff H. Lipton, PhD, MD
Journal: Blood
Blood (2013) 122 (21): 2723.
https://doi.org/10.1182/blood.V122.21.2723.2723
Published: 2013
Journal Articles

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Jorge E. Cortes, MD, H. Jean Khoury, MD, Andreas Hochhaus, MD, Jane F Apperley, MD, Stephen G. O'Brien, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Maureen G. Conlan, MD, Hagop M. Kantarjian, MD, Tim H. Brümmendorf, MD
Journal: Blood
Blood (2013) 122 (21): 1484.
https://doi.org/10.1182/blood.V122.21.1484.1484
Published: 2013
Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Jeff H. Lipton, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2013) 122 (21): 4025.
https://doi.org/10.1182/blood.V122.21.4025.4025
Published: 2013